Radiotherapy alone for stage IE ocular adnexal mucosa-associated lymphoid tissue lymphomas: long-term results.
Cataract
MALT lymphoma
Ocular adnexal
Radiation therapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
30 Jan 2020
30 Jan 2020
Historique:
received:
18
09
2019
accepted:
21
01
2020
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
21
10
2020
Statut:
epublish
Résumé
To evaluate the long-term efficacy and toxicity of radiation therapy in patients with Stage IE primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. We designed a retrospective analysis to evaluate 81 patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy between 2006 and 2016. The median radiation dose was 30 Gy (range, 30-36 Gy in 15-18 fractions). Local control, progression-free survival, overall survival, and cumulative incidence of Grade 3 cataract were calculated by using the Kaplan-Meier method. The median follow-up time was 74 months (range, 4-157 months). The 5-year local control was 100%. Although local relapse was suspected in 3 patients after radiation therapy, 2 patients were pathologically diagnosed as IgG4-related inflammation and in 1 patient as intense inflammatory cell infiltration. The 5-year progression-free survival was 94.4%. Five patients had relapse at distant sites. The 5-year overall survival was 98.8%. Twenty patients had Grade 3 cataract. The 5-year cumulative incidences of Grade ≥ 3 and Grade ≥ 2 cataract for 58 patients treated without a lens shield were 38 and 40%, respectively. The incidence of Grade ≥ 3 cataract was 42% for 50 patients treated with 6-MV X-rays (estimated lens dose: 29 Gy) and 17% for 8 patients treated with 9-MeV electrons (estimated lens dose: 24 Gy). Radiation therapy alone yielded excellent local control and long-term survival in Stage IE ocular adnexal mucosa-associated lymphoid tissue lymphoma. Long-term observation with careful attention to relapse at distant sites is necessary. In the case of suspected local relapse, IgG4-related disease should be carefully ruled out.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the long-term efficacy and toxicity of radiation therapy in patients with Stage IE primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.
METHODS
METHODS
We designed a retrospective analysis to evaluate 81 patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy between 2006 and 2016. The median radiation dose was 30 Gy (range, 30-36 Gy in 15-18 fractions). Local control, progression-free survival, overall survival, and cumulative incidence of Grade 3 cataract were calculated by using the Kaplan-Meier method.
RESULT
RESULTS
The median follow-up time was 74 months (range, 4-157 months). The 5-year local control was 100%. Although local relapse was suspected in 3 patients after radiation therapy, 2 patients were pathologically diagnosed as IgG4-related inflammation and in 1 patient as intense inflammatory cell infiltration. The 5-year progression-free survival was 94.4%. Five patients had relapse at distant sites. The 5-year overall survival was 98.8%. Twenty patients had Grade 3 cataract. The 5-year cumulative incidences of Grade ≥ 3 and Grade ≥ 2 cataract for 58 patients treated without a lens shield were 38 and 40%, respectively. The incidence of Grade ≥ 3 cataract was 42% for 50 patients treated with 6-MV X-rays (estimated lens dose: 29 Gy) and 17% for 8 patients treated with 9-MeV electrons (estimated lens dose: 24 Gy).
CONCLUSIONS
CONCLUSIONS
Radiation therapy alone yielded excellent local control and long-term survival in Stage IE ocular adnexal mucosa-associated lymphoid tissue lymphoma. Long-term observation with careful attention to relapse at distant sites is necessary. In the case of suspected local relapse, IgG4-related disease should be carefully ruled out.
Identifiants
pubmed: 32000814
doi: 10.1186/s13014-020-1477-8
pii: 10.1186/s13014-020-1477-8
pmc: PMC6993363
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Références
Cancer. 2010 Aug 15;116(16):3815-24
pubmed: 20564130
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):650-4
pubmed: 24521680
Korean J Ophthalmol. 2013 Aug;27(4):243-8
pubmed: 23908569
Blood. 1997 Jun 1;89(11):3909-18
pubmed: 9166827
Hematology Am Soc Hematol Educ Program. 2009;:523-31
pubmed: 20008237
Radiat Oncol J. 2017 Sep;35(3):249-256
pubmed: 29037024
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):657-63
pubmed: 11849787
Am J Surg Pathol. 2000 May;24(5):623-39
pubmed: 10800981
Anticancer Res. 2015 Jun;35(6):3591-7
pubmed: 26026132
J Natl Cancer Inst. 2004 Apr 21;96(8):586-94
pubmed: 15100336
N Engl J Med. 1994 May 5;330(18):1267-71
pubmed: 8145781
Med Sci Monit. 2015 Apr 10;21:1043-50
pubmed: 25858500
Lancet. 1995 Jun 24;345(8965):1591-4
pubmed: 7783535
Blood. 1994 Sep 1;84(5):1361-92
pubmed: 8068936
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):11-31
pubmed: 25863750
N Engl J Med. 1998 Mar 19;338(12):804-10
pubmed: 9504941
J Clin Oncol. 2003 Nov 15;21(22):4157-64
pubmed: 14615444
Head Neck. 2017 Jun;39(6):1095-1100
pubmed: 28370694
Leuk Lymphoma. 2013 Mar;54(3):491-6
pubmed: 23020137
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1058-66
pubmed: 11958902
Cancer. 1983 Oct 15;52(8):1410-6
pubmed: 6193858
Br J Ophthalmol. 1999 Jun;83(6):742-7
pubmed: 10340987
Pathol Int. 1998 May;48(5):323-31
pubmed: 9704338
Ann Oncol. 1998 Jul;9(7):717-20
pubmed: 9739436
Blood. 2000 Jul 15;96(2):410-9
pubmed: 10887100
J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82
pubmed: 17018784
Radiat Oncol. 2018 May 16;13(1):95
pubmed: 29769097
EClinicalMedicine. 2018 Oct 17;4-5:32-42
pubmed: 31193655
Infect Agent Cancer. 2012 Apr 02;7:8
pubmed: 22472082
Hematology. 2016 Oct;21(9):542-8
pubmed: 27168138
J Natl Cancer Inst. 2006 Jul 5;98(13):936-9
pubmed: 16818858
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1509-14
pubmed: 21664061
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cancer. 2013 Feb 1;119(3):629-38
pubmed: 22893605
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):31-6
pubmed: 10219791
J Clin Oncol. 1998 Aug;16(8):2780-95
pubmed: 9704731
Am J Ophthalmol. 2019 Mar;199:44-57
pubmed: 30419193
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64
pubmed: 11483337